These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28433511)

  • 1. Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists.
    Tokumaru K; Ito Y; Nomura I; Nakahata T; Shimizu Y; Kurimoto E; Aoyama K; Aso K
    Bioorg Med Chem; 2017 Jun; 25(12):3098-3115. PubMed ID: 28433511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists.
    Nakahata T; Tokumaru K; Ito Y; Ishii N; Setoh M; Shimizu Y; Harasawa T; Aoyama K; Hamada T; Kori M; Aso K
    Bioorg Med Chem; 2018 May; 26(8):1598-1608. PubMed ID: 29478803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
    Nishiyama K; Suzuki H; Harasawa T; Suzuki N; Kurimoto E; Kawai T; Maruyama M; Komatsu H; Sakuma K; Shimizu Y; Shimojo M
    J Pharmacol Exp Ther; 2017 Nov; 363(2):253-264. PubMed ID: 28851764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52.
    Setoh M; Ishii N; Kono M; Miyanohana Y; Shiraishi E; Harasawa T; Ota H; Odani T; Kanzaki N; Aoyama K; Hamada T; Kori M
    J Med Chem; 2014 Jun; 57(12):5226-37. PubMed ID: 24884590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior.
    Wang P; Felsing DE; Chen H; Stutz SJ; Murphy RE; Cunningham KA; Allen JA; Zhou J
    J Med Chem; 2020 Nov; 63(22):13951-13972. PubMed ID: 33198466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in Vitro Antifungal Activities of Novel Benzamide Derivatives Containing a Triazole Moiety.
    Zhang W; Sui G; Li Y; Fang M; Yang X; Ma X; Zhou W
    Chem Pharm Bull (Tokyo); 2016; 64(6):616-24. PubMed ID: 27250796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Amide Bioisosteres Leading to 1,2,3-Triazole Containing Compounds as GPR88 Agonists: Design, Synthesis, and Structure-Activity Relationship Studies.
    Rahman MT; Decker AM; Laudermilk L; Maitra R; Ma W; Ben Hamida S; Darcq E; Kieffer BL; Jin C
    J Med Chem; 2021 Aug; 64(16):12397-12413. PubMed ID: 34387471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27.
    Pillaiyar T; Rosato F; Wozniak M; Blavier J; Charles M; Laschet C; Kronenberger T; Müller CE; Hanson J
    Eur J Med Chem; 2021 Dec; 225():113777. PubMed ID: 34454125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A
    Nishiyama K; Suzuki H; Maruyama M; Yoshihara T; Ohta H
    Brain Res; 2017 Sep; 1670():24-31. PubMed ID: 28583861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel and potent small-molecule urotensin II receptor agonists.
    Lehmann F; Currier EA; Clemons B; Hansen LK; Olsson R; Hacksell U; Luthman K
    Bioorg Med Chem; 2009 Jul; 17(13):4657-65. PubMed ID: 19481466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
    Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
    Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of ligand recognition and self-activation of orphan GPR52.
    Lin X; Li M; Wang N; Wu Y; Luo Z; Guo S; Han GW; Li S; Yue Y; Wei X; Xie X; Chen Y; Zhao S; Wu J; Lei M; Xu F
    Nature; 2020 Mar; 579(7797):152-157. PubMed ID: 32076264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.
    Xu YJ; Miao HQ; Pan W; Navarro EC; Tonra JR; Mitelman S; Camara MM; Deevi DS; Kiselyov AS; Kussie P; Wong WC; Liu H
    Bioorg Med Chem Lett; 2006 Jan; 16(2):404-8. PubMed ID: 16246551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
    Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H
    Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors.
    Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P
    Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists.
    Chen SR; Ke YY; Yeh TK; Lin SY; Ou LC; Chen SC; Chang WT; Chang HF; Wu ZH; Hsieh CC; Law PY; Loh HH; Shih C; Lai YK; Yeh SH; Ueng SH
    Eur J Med Chem; 2017 Jan; 126():202-217. PubMed ID: 27776274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
    Mao W; Ning M; Liu Z; Zhu Q; Leng Y; Zhang A
    Bioorg Med Chem; 2012 May; 20(9):2982-91. PubMed ID: 22459213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.